Clinical Trials on Purpura Thrombocytopenic

Total 1001 results

Eisai Inc.

Completed

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Idiopathic Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Immune Thrombocytopenic Purpura

United States
Assiut University

Unknown

Lymphocyte Counts in Immune Thrombocytopenic Purpura

Thrombocytopenic Purpura
Shandong University
The First Affiliated Hospital of Anhui Medical University; The Affiliated Hospital... and other collaborators

Completed

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Completed

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Hoffmann-La Roche

Completed

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

Italy
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

Immune Thrombocytopenic Purpura

Mexico
Samsung Medical Center

Completed

Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura

Korea, Republic of
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

Immune Thrombocytopenic Purpura

Mexico
Cooperative Study Group A for Hematology

Completed

High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP

Idiopathic Thrombocytopenic Purpura

Korea, Republic of
Amgen

Completed

Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

Idiopathic Thrombocytopenic Purpura
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenic Purpura

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

Primary Immune Thrombocytopenia

China
Shandong University

Recruiting

High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

ITP - Immune Thrombocytopenia

China
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
Shandong University

Recruiting

Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

Primary Immune Thrombocytopenia

China
Kyowa Kirin China Pharmaceutical Co., Ltd.

Completed

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP)

China
UCB Biopharma SRL
Parexel

Completed

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Thrombocytopenia

Australia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Republic of, Poland, Romania, Spain, United Kingdom
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
UCB Biopharma SRL

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2)

Primary Immune Thrombocytopenia

United States, Bulgaria, China, France, Germany, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Henri Mondor University Hospital

Completed

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Primary Immune Thrombocytopenia
Peking University People's Hospital
Qilu Hospital of Shandong University; Beijing Tongren Hospital; Beijing Municipal... and other collaborators

Completed

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Autoimmune Thrombocytopenia

China
Henri Mondor University Hospital
Roche Pharma AG

Unknown

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia. (ITP-RITUX)

Purpura, Thrombocytopenic, Idiopathic | Autoimmune Thrombocytopenia

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients. (ITP0614)

Adult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimetics

Italy
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
European Research Consortium on ITP
Fondazione Progetto Ematologia

Completed

Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

Primary Immune Thrombocytopenia (ITP)

Spain, Switzerland, United Kingdom, Italy, France, Norway
University Children's Hospital Basel
Novartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaborators

Active, not recruiting

Immunomodulation With Eltrombopag in ITP (iROM2)

Primary Immune Thrombocytopenia (ITP)

Switzerland
University Hospital, Rouen

Not yet recruiting

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study (PEX-FREE)

Thrombotic Microangiopathies
New York Medical College

Recruiting

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura (NYMC207)

Immune Thrombocytopenic Purpura

United States
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Idiopathic Thrombocytopenic Purpura

Japan
Amgen

Completed

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura
Amgen

Completed

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenic Purpura
Amgen

Completed

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Nayera Hazaa Elsherif

Completed

The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

Idiopathic Thrombocytopenic Purpura

Egypt
Assiut University

Completed

Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level

Idiopathic Thrombocytopenic Purpura

Egypt
Copenhagen University Hospital at Herlev

Completed

The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

Denmark
Grifols Biologicals, LLC
Instituto Grifols, S.A.

Completed

IGIV Study for Chronic ITP Patients Ages 3-70

Idiopathic Thrombocytopenic Purpura

United States, India, Puerto Rico, Canada
Ming Hou
Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaborators

Completed

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Shandong University

Withdrawn

All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Amgen

Completed

Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training

Immune Thrombocytopenic Purpura

Spain, Austria, Belgium, Greece, United Kingdom, France, Germany, Netherlands
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Idiopathic Thrombocytopenic Purpura

Australia
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Initial Treatment of Patients With Immune Thrombocytopenic Purpura (ITP^2)

Immune Thrombocytopenic Purpura

United States
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Ingrid Pabinger, MD
GlaxoSmithKline

Completed

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag (PLATEFUN)

Idiopathic Thrombocytopenic Purpura
University of Aarhus
Kjaersgaard, Mimi, M.D.

Completed

Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D

Idiopathic Thrombocytopenic Purpura

Denmark
Assistance Publique - Hôpitaux de Paris
Etablissement Français du Sang

Terminated

Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy

Autoimmune Thrombocytopenic Purpura

France
Octapharma

Completed

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Primary Thrombocytopenia

Germany

Clinical Trials on Purpura Thrombocytopenic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations